|
From Medical Economics Physicians who serve on boards or as expert advisers to publicly traded companies should proceed with caution when exposed to new drugs, devices or other healthcare innovations before members of the public. Acting on insider information can lead to serious consequences. Here’s what you need to know.
Read more
|